<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Cir Bras</journal-id><journal-id journal-id-type="iso-abbrev">Acta Cir Bras</journal-id><journal-id journal-id-type="publisher-id">acb</journal-id><journal-title-group><journal-title>Acta Cir&#x000fa;rgica Brasileira</journal-title></journal-title-group><issn pub-type="ppub">0102-8650</issn><issn pub-type="epub">1678-2674</issn><publisher><publisher-name>Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7006370</article-id><article-id pub-id-type="other">00213</article-id><article-id pub-id-type="doi">10.1590/s0102-865020190120000006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group><subject>Clinical Investigation</subject></subj-group></article-categories><title-group><article-title>Comparative study on the efficacy of non-steroidal, steroid and non-use of anti-inflammatory in the treatment of acute epidemic conjunctivitis <xref ref-type="fn" rid="fn1">
<sup>1</sup>
</xref>
</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9412-4706</contrib-id><name><surname>Santiago</surname><given-names>Luiz Alfredo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>I</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8210-9055</contrib-id><name><surname>da Silva</surname><given-names>Jussara Matyelle Rodrigues</given-names></name><xref ref-type="aff" rid="aff2">
<sup>II</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4530-0093</contrib-id><name><surname>de Azevedo</surname><given-names>Orle&#x000e2;ncio Gomes Ripardo</given-names></name><xref ref-type="aff" rid="aff3">
<sup>III</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Vasconcelos</surname><given-names>Paulo Roberto Leit&#x000e3;o</given-names></name><xref ref-type="aff" rid="aff4">
<sup>IV</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>I</label> Master in Surgery, and Physician, Hospital de Olhos Leiria de Andrade, Fortaleza-CE, Brazil. Acquisition of data, technical procedures, manuscript writing.</aff><aff id="aff2">
<label>II</label> Fellow Master degree, Pharmacology Department, Universidade Federal do Cear&#x000e1; (UFC), Fortaleza-CE, Brazil. Statistical analysis, analysis and interpretation of data, technical procedures.</aff><aff id="aff3">
<label>III</label> Pos Doc, Postgraduate Program, Department of Surgery, UFC, Fortaleza-CE, Brazil. Manuscript preparation and writing, critical revision</aff><aff id="aff4">
<label>IV</label> PhD, Full Professor, Coordinator, Postgraduate Program in Surgery, Department of Surgery, UFC, Fortaleza-CE, Brazil. Intellectual and scientific content of the study, critical revision, final approval.</aff><author-notes><corresp id="c01"> Correspondence: Orle&#x000e2;ncio Gomes Ripardo de Azevedo Rua Prof. Costa Mendes, 1608/3&#x000ba; andar, Bloco Did&#x000e1;tico 60430-140 Fortaleza &#x02013; CE Brasil Tels. (55 85)3366-8061 / 3366-8062 <email>orleancio@gmail.com</email></corresp><fn fn-type="COI-statement"><p>Conflict of interest: none</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>7</day><month>2</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2019</year></pub-date><volume>34</volume><issue>12</issue><elocation-id>e201901206</elocation-id><history><date date-type="received"><day>05</day><month>8</month><year>2019</year></date><date date-type="rev-recd"><day>08</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p></license></permissions><abstract><title>Abstract</title><sec><title>Purpose</title><p> To evaluate the effects of prednisolone against sodium diclofenac both with ciprofloxacin compared to artificial tears on the symptoms and signs of acute viral conjunctivitis.</p></sec><sec><title>Methods</title><p> Study included 37 patients diagnosed with acute conjunctivitis and distributed by three groups: A (1% prednisolone acetate + ciprofloxacin (0.3%); B (Sodium diclofenac (0.1%) + ciprofloxacin (0.3%) and C (artificial tears + ciprofloxacin (0.3%). Patients received medication 6/6 hours daily. Signs and symptoms (e.g. lacrimation, burning, photophobia, etc.) were scored at baseline and on the first, third, fifth and seventh days and in the end of treatment using a standardized questionnaire and slit lamp anterior segment examination.</p></sec><sec><title>Results</title><p> All three groups demonstrated an improvement in the signs and symptoms of conjunctivitis in their follow-up visits. There was no significant difference in symptom and sign scores between Group A and B and B and C in the study visits ( <italic>p</italic> &#x0003e;0.05). However, the comparison between groups A and C showed a clinical trend (p=0.05) on third evaluation suggesting better clinical action using the corticosteroids.</p></sec><sec><title>Conclusion</title><p> The prednisolone acetate was not superior to the use of sodium diclofenac or artificial tears in relieving the signs and symptoms of viral conjunctivitis.</p></sec></abstract><kwd-group><kwd>Conjunctivitis</kwd><kwd>Adrenal Cortex Hormones</kwd><kwd>Cytokines</kwd></kwd-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="30"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Approximately 70% of patients with acute conjunctivitis present to their primary care provider or an urgent care center rather than to an ophthalmologist<sup><xref ref-type="fn" rid="fn1">1</xref></sup> . Conjunctivitis is a common complaint in primary care, affecting all ages and socioeconomic classes affecting 6 million people annually in the United States<sup><xref rid="B2" ref-type="bibr">2</xref> , <xref rid="B3" ref-type="bibr">3</xref></sup> .</p><p>Infectious conjunctivitis can have several etiologic factors, such as bacterial, viral, chlamydial, fungal, and parasitic. In addition, non-infectious conjunctivitis includes allergens, toxicities, and irritants<sup><xref rid="B4" ref-type="bibr">4</xref></sup> .</p><p>Common viral agents include adenovirus, herpes simplex, herpes zoster, and enterovirus. Allergic conjunctivitis encompasses seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis<sup><xref rid="B4" ref-type="bibr">4</xref></sup> .</p><p>Conjunctivitis can be further divided into acute or chronic types. Acute conjunctivitis is characterized by onset within 3 to 4 weeks of the presentation and chronic is defined as more than 4 weeks in duration<sup><xref rid="B5" ref-type="bibr">5</xref></sup> .</p><p>Acute conjunctivitis is usually a self-limiting condition; however, it is important to rule out other sight-threatening red eye diseases. Viral conjunctivitis is an extremely common cause of conjunctivitis, with estimates as high as 80% of all causes of acute conjunctivitis<sup><xref rid="B6" ref-type="bibr">6</xref></sup> .</p><p>As many as 90% of these cases of viral conjunctivitis are thought to be caused by human adenovirus, which is known to cause 2 distinct syndromes: epidemic keratoconjunctivitis and pharyngoconjunctival fever<sup><xref rid="B7" ref-type="bibr">7</xref></sup> .</p><p>Viral conjunctivitis is highly contagious<sup><xref ref-type="fn" rid="fn1">1</xref> ,5</sup>. The virus spreads through direct contact via contaminated fingers, medical instruments, swimming pool water, or personal items; in one study, 46% of infected people had positive cultures grown from swabs of their hands<sup><xref rid="B8" ref-type="bibr">8</xref></sup> . Because of the high rates of transmission, hand washing, strict instrument disinfection, and isolation of the infected patients from the rest of the clinic has been advocated<sup><xref rid="B9" ref-type="bibr">9</xref></sup> . Incubation and communicability are estimated to be 5 to 12 days and 10 to 14 days, respectively<sup><xref rid="B10" ref-type="bibr">10</xref></sup> .</p><p>Although no effective treatment exists, artificial tears, topical antihistamines, or cold compresses may be useful in alleviating some of the symptoms<sup><xref rid="B11" ref-type="bibr">11</xref></sup> . Available antiviral medications are not useful<sup><xref rid="B10" ref-type="bibr">10</xref></sup> and topical antibiotics are not indicated<sup><xref rid="B11" ref-type="bibr">11</xref></sup> .</p><p>In hospitalized patients, a randomized study compared topical ketorolac 0.5% and indomethacin 0.1% to artificial tears<sup><xref rid="B12" ref-type="bibr">12</xref></sup> . Ketorolac and indomethacin were more effective in decreasing conjunctival hyperemia, but burning, foreign--body sensations, and photophobia were unaffected. In a different randomized study of 117 patients, topical ketorolac 0.5% used four times daily was no better than artificial tears in relieving signs (conjunctival injection, chemosis, mucus, and lid edema) and symptoms (itching, foreign body sensation, tearing, redness, lid swelling, and overall discomfort) of viral conjunctivitis<sup><xref rid="B13" ref-type="bibr">13</xref></sup> .</p><p>In a rabbit ocular model to evaluate antiviral activity, neither 0.5% ketorolac nor 0.1% diclofenac demonstrated inhibitory activity on viral replication or the formation of subepithelial immune infiltrates. In contrast, 1% prednisolone acetate prolonged viral shedding. Thus, the objective of this study was to evaluate the effects of the administration of prednisolone against sodium diclofenac both associated with ciprofloxacin compared to artificial tears on the symptoms and signs of acute viral conjunctivitis.</p></sec><sec sec-type="methods"><title>Methods</title><p>The research project, with the experimental protocol and the consent term, was submitted to the Research Ethics Committee, Universidade Federal do Cear&#x000e1;, accredited by CONEP &#x02013; Conselho Nacional de Sa&#x000fa;de / MS and approved - Protocol No. 118/11 according with the Helsinki Declaration of 1975 as revised in 2008. All the protocols were adequate to the resolution 466/12 of Health Ministry.</p><p>In the current study, 37 patients, 20 women and 17 men, were divided into 3 groups; A (n=16), B (n=5) and C (n=16), constituting people of both genders with ages between 18 and 70 years. Patients were invited based on clinical history and slit lamp examination, where they were examined prior to initiation of treatment and at the end of the study, being followed up every 3 days.</p><p>To guarantee the homogeneity of the characteristics between the study groups, a block randomization was adopted<sup><xref rid="B11" ref-type="bibr">11</xref></sup> . Fixed-size blocks of nine envelopes were used, of which 3 were with medication group A, 3 with group B and 3 with group C. At the beginning of each block a lottery was made to indicate which medication to use.</p><p>The medication was administered for 15 days of treatment with corticoid eye drops (1% prednisolone acetate) and sodium diclofenac sodium eye drops. Antibiotic eye drops (ciprofloxacin 0.3%) were also used, because it is common for epidemic conjunctivitis of viral cause, to complicate with a bacterial infection <sup><xref rid="B12" ref-type="bibr">12</xref></sup> . For the relief of symptoms in group C, artificial tears were used.</p><sec><title>Symptoms assessment</title><p>For overall assessment of relief, patients answered the following question: Do you consider the relief of conjunctivitis symptoms satisfactory during the last 15 days? The answer was yes or no.</p></sec><sec><title>Inflammatory markers panel</title><p>Dosage of inflammatory mediators: through conjunctival smears and conjunctival secretion, with an absorbent ophthalmic sponge, performed only in the most symptomatic eye<sup><xref rid="B13" ref-type="bibr">13</xref> , <xref rid="B14" ref-type="bibr">14</xref></sup> , at the last evaluation. The kit - cat HCYTOMAG - 60K - 07 was used to measure the following cytokines: IFNg, IL &#x02013; 1a, IL - 6, IL - 8, IL - 10, IL - 13, TNF-a. Kit 46-702 MAG / MILLIPLEX MAP<sup>&#x024c7;</sup>, for NFkB. Kit cat # MBS723617 for iNOS.</p><p>After collection the sponge was placed in the 1.5ml Eppendorf<sup>&#x024c7;</sup> tube, where they were centrifuged 5 minutes at 8000rpm. With forceps the sponge was disposed. For analysis it was ideal to obtain at least 40 microliters. Samples were stored in a drum with liquid nitrogen.</p></sec><sec><title>Statistics</title><p>The Friedman test was applied in each group and in total. When the independent variable had three or more groups ANOVA was used with Bonferri posttest for multiple comparisons. The P&#x0003c;0.05 was considered to characterize the statistical difference between the groups.</p></sec></sec><sec sec-type="results"><title>Results</title><p>This report analyzed 37 patients, 54.1% (20/37) female and 45.9% (17/37) male. The study divided the subjects in three groups A, B and C, all the patients did not demonstrate any significant difference, in the beginning of the experiment, between the median of symptoms 36.8 (&#x000b1;1.9), 29.8 (&#x000b1;2.8), and 32.1(&#x000b1;2.2) respectively ( <xref rid="t1" ref-type="table">Table 1</xref> ).</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Comparison of means of symptoms by group and period, with 95% CI.</title></caption><table frame="hsides" rules="groups"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Evaluations</th><th rowspan="1" colspan="1">A</th><th rowspan="1" colspan="1">B</th><th rowspan="1" colspan="1">C</th><th rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Pre-study</td><td align="center" rowspan="1" colspan="1">36.8 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">29.8 (&#x000b1;2.8)</td><td align="center" rowspan="1" colspan="1">32.1 (&#x000b1;2.2)</td><td align="center" rowspan="1" colspan="1">33.8 (&#x000b1;1.4)</td></tr><tr><td rowspan="1" colspan="1">1st evaluation</td><td align="center" rowspan="1" colspan="1">26.2 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">26.3 (&#x000b1;2.0)</td><td align="center" rowspan="1" colspan="1">25.1 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">25.7 (&#x000b1;1.1)</td></tr><tr><td rowspan="1" colspan="1">2nd evaluation</td><td align="center" rowspan="1" colspan="1">11.9 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">15.7 (&#x000b1;4.0)</td><td align="center" rowspan="1" colspan="1">17.9 (&#x000b1;2.4)</td><td align="center" rowspan="1" colspan="1">15.0 (&#x000b1;1.4)</td></tr><tr><td rowspan="1" colspan="1">3rd evaluation</td><td align="center" rowspan="1" colspan="1">5.8 (&#x000b1;1.1)</td><td align="center" rowspan="1" colspan="1">14.1 (&#x000b1;3.8)</td><td align="center" rowspan="1" colspan="1">13.4 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">10.2 (&#x000b1;1.2)</td></tr><tr><td rowspan="1" colspan="1">4th evaluation</td><td align="center" rowspan="1" colspan="1">1.1 (&#x000b1;0.5)</td><td align="center" rowspan="1" colspan="1">10.2 (&#x000b1;3.6)</td><td align="center" rowspan="1" colspan="1">5.3 (&#x000b1;1.3)</td><td align="center" rowspan="1" colspan="1">4.1 (&#x000b1;0.9)</td></tr><tr><td rowspan="1" colspan="1">Closing</td><td align="center" rowspan="1" colspan="1">0.0 (&#x000b1;0.0)</td><td align="center" rowspan="1" colspan="1">6.7 (&#x000b1;2.4)</td><td align="center" rowspan="1" colspan="1">1.1 (&#x000b1;0.4)</td><td align="center" rowspan="1" colspan="1">1.4 (&#x000b1;0.5)</td></tr><tr><td rowspan="1" colspan="1">P-value*</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>The table shows the means of symptoms along the points of evaluation during the treatment demonstrating a decreasing of the symptoms despite of the protocol of treatment.</p></fn><fn id="TFN2"><p>The values correspond to the following nomenclature: mean (&#x000b1; 95% CI).</p></fn><fn id="TFN3"><p>*Friedman test.</p></fn><fn id="TFN4"><p>Source: Data generated by the author.</p></fn></table-wrap-foot></table-wrap>
</p><p>All patients demonstrated a decrease in the symptom severity during the period of evaluation. However, group A demonstrated an important decrease of 54.5% from the 1<sup>st</sup> to 2<sup>nd</sup> evaluation, while groups B and C showed a decrease of 40.3% and 28.9% respectively. Group A (n=16) received prednisolone (1%) plus ciprofloxacin (0.3%) demonstrated a trend in improvement of the symptoms when compared to group C (n=16) that received artificial tears plus ciprofloxacin (0.3%) in third evaluation (p=0.055); however, no statistical difference was observed between A and B or between B and C groups in the 1<sup>st</sup>, 2<sup>nd</sup> 3<sup>rd</sup>, 4<sup>th</sup> evaluation and in the last assessment respectively ( <xref rid="t2" ref-type="table">Table 2</xref> ).</p><p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Comparison of means of symptoms between groups, by period, with 95% CI.</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Period of evaluation</th><th rowspan="3" colspan="1">A</th><th rowspan="3" colspan="1">B</th><th rowspan="3" colspan="1">C</th><th colspan="3" rowspan="1">P-value</th></tr><tr><th colspan="3" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">A -- B</th><th rowspan="1" colspan="1">A -- C</th><th rowspan="1" colspan="1">B -- C</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Pre-study</td><td align="center" rowspan="1" colspan="1">18.8 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">15.2 (&#x000b1;2.8)</td><td align="center" rowspan="1" colspan="1">16.4 (&#x000b1;2.2)</td><td align="center" rowspan="1" colspan="1">0.981</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">1st evaluation</td><td align="center" rowspan="1" colspan="1">13.4 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">13.4 (&#x000b1;2.0)</td><td align="center" rowspan="1" colspan="1">12.8 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">2nd evaluation</td><td align="center" rowspan="1" colspan="1">6.1 (&#x000b1;1.8)</td><td align="center" rowspan="1" colspan="1">8.0 (&#x000b1;4.0)</td><td align="center" rowspan="1" colspan="1">9.1 (&#x000b1;2.4)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td><td align="center" rowspan="1" colspan="1">0.996</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">3rd evaluation</td><td align="center" rowspan="1" colspan="1">2.9 (&#x000b1;1.1)</td><td align="center" rowspan="1" colspan="1">7.2 (&#x000b1;3.8)</td><td align="center" rowspan="1" colspan="1">6.8 (&#x000b1;1.9)</td><td align="center" rowspan="1" colspan="1">0.944</td><td align="center" rowspan="1" colspan="1">0.055</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">4th evaluation</td><td align="center" rowspan="1" colspan="1">0.6 (&#x000b1;0.5)</td><td align="center" rowspan="1" colspan="1">5.2 (&#x000b1;3.6)</td><td align="center" rowspan="1" colspan="1">2.7 (&#x000b1;1.3)</td><td align="center" rowspan="1" colspan="1">0.538</td><td align="center" rowspan="1" colspan="1">0.307</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">Closing</td><td align="center" rowspan="1" colspan="1">0.0 (&#x000b1;0.00)</td><td align="center" rowspan="1" colspan="1">3.40 (&#x000b1;2.45)</td><td align="center" rowspan="1" colspan="1">0.6 (&#x000b1;0.4)</td><td align="center" rowspan="1" colspan="1">0.301</td><td align="center" rowspan="1" colspan="1">0.757</td><td align="center" rowspan="1" colspan="1">0.857</td></tr></tbody></table><table-wrap-foot><attrib>Source: Data generated by the author.</attrib><fn id="TFN5"><p>The values correspond to the following nomenclature: mean (&#x000b1; 95% CI).</p></fn><fn id="TFN6"><p>*Friedman test.</p></fn></table-wrap-foot></table-wrap>
</p><p>Collected tears were assessed for inflammation using an inflammatory marker panel as described in methods. There were no statistical differences observed between the groups studied, IFNg (p=0.447), IL-10 (0.505), IL-13 (0.641), IL-1a (0.859); IL-8 (0.177); TNF-a (0.735) ( <xref rid="t3" ref-type="table">Table 3</xref> ).</p><p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Levels of inflammatory markers in groups A, B and C.</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Mediator</th><th rowspan="3" colspan="1">Median</th><th rowspan="3" colspan="1">IC 95%</th><th colspan="2" rowspan="1">Group A</th><th colspan="2" rowspan="1">Group B</th><th colspan="2" rowspan="1">Group C</th><th rowspan="3" colspan="1">P-value</th></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">IC 95%</th><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">IC 95%</th><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">IC 95%</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">IFNy</td><td align="center" rowspan="1" colspan="1">4.58</td><td align="center" rowspan="1" colspan="1">(1.91 &#x02013; 11.05)</td><td align="center" rowspan="1" colspan="1">2.80</td><td align="center" rowspan="1" colspan="1">(1.10 &#x02013; 11.05)</td><td align="center" rowspan="1" colspan="1">28.37</td><td align="center" rowspan="1" colspan="1">(1.39 &#x02013; 467.00)</td><td align="center" rowspan="1" colspan="1">8.01</td><td align="center" rowspan="1" colspan="1">(2.94 &#x02013; 19.15)</td><td align="center" rowspan="1" colspan="1">0.447</td></tr><tr><td rowspan="1" colspan="1">IL-10</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">(2.64 &#x02013; 27.06)</td><td align="center" rowspan="1" colspan="1">5.31</td><td align="center" rowspan="1" colspan="1">(1.45 &#x02013; 23.97)</td><td align="center" rowspan="1" colspan="1">206.43</td><td align="center" rowspan="1" colspan="1">(1.33 &#x02013; 775.00)</td><td align="center" rowspan="1" colspan="1">23.29</td><td align="center" rowspan="1" colspan="1">(5.54 &#x02013; 53.34)</td><td align="center" rowspan="1" colspan="1">0.505</td></tr><tr><td rowspan="1" colspan="1">IL-13</td><td align="center" rowspan="1" colspan="1">17.07</td><td align="center" rowspan="1" colspan="1">(11.88 &#x02013; 26.67)</td><td align="center" rowspan="1" colspan="1">18.42</td><td align="center" rowspan="1" colspan="1">(2.79 &#x02013; 30.22)</td><td align="center" rowspan="1" colspan="1">12.38</td><td align="center" rowspan="1" colspan="1">(12.38 &#x02013; 19.81)</td><td align="center" rowspan="1" colspan="1">25.50</td><td align="center" rowspan="1" colspan="1">(8.54 &#x02013; 43.45)</td><td align="center" rowspan="1" colspan="1">0.641</td></tr><tr><td rowspan="1" colspan="1">IL-1a</td><td align="center" rowspan="1" colspan="1">11.70</td><td align="center" rowspan="1" colspan="1">(8.55 &#x02013; 21.59)</td><td align="center" rowspan="1" colspan="1">11.79</td><td align="center" rowspan="1" colspan="1">(4.24 &#x02013; 43.81)</td><td align="center" rowspan="1" colspan="1">57.28</td><td align="center" rowspan="1" colspan="1">(0.45 &#x02013; 133.00)</td><td align="center" rowspan="1" colspan="1">11.70</td><td align="center" rowspan="1" colspan="1">(8.11 &#x02013; 22.58)</td><td align="center" rowspan="1" colspan="1">0.859</td></tr><tr><td rowspan="1" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">20.03</td><td align="center" rowspan="1" colspan="1">(13.52 &#x02013; 35.62)</td><td align="center" rowspan="1" colspan="1">9.46</td><td align="center" rowspan="1" colspan="1">(5.97 &#x02013; 22.10)</td><td align="center" rowspan="1" colspan="1">74.81</td><td align="center" rowspan="1" colspan="1">(6.24 &#x02013; 618.00)</td><td align="center" rowspan="1" colspan="1">26.22</td><td align="center" rowspan="1" colspan="1">(17.66 &#x02013; 70.19)</td><td align="center" rowspan="1" colspan="1">0.184</td></tr><tr><td rowspan="1" colspan="1">IL-8</td><td align="center" rowspan="1" colspan="1">441.00</td><td align="center" rowspan="1" colspan="1">(254.00 &#x02013; 681.00)</td><td align="center" rowspan="1" colspan="1">445.00</td><td align="center" rowspan="1" colspan="1">(215.00 &#x02013; 681.00)</td><td align="center" rowspan="1" colspan="1">1366.50</td><td align="center" rowspan="1" colspan="1">(254.00 &#x02013; 2927.00)</td><td align="center" rowspan="1" colspan="1">254.00</td><td align="center" rowspan="1" colspan="1">(94.61 &#x02013; 803.00)</td><td align="center" rowspan="1" colspan="1">0.177</td></tr><tr><td rowspan="1" colspan="1">TNFa</td><td align="center" rowspan="1" colspan="1">10.98</td><td align="center" rowspan="1" colspan="1">(5.63 &#x02013; 26.36)</td><td align="center" rowspan="1" colspan="1">12.79</td><td align="center" rowspan="1" colspan="1">(2.71 &#x02013; 37.81)</td><td align="center" rowspan="1" colspan="1">69.28</td><td align="center" rowspan="1" colspan="1">(0.68 &#x02013; 928.00)</td><td align="center" rowspan="1" colspan="1">8.81</td><td align="center" rowspan="1" colspan="1">(5.63 &#x02013; 28.12)</td><td align="center" rowspan="1" colspan="1">0.735</td></tr><tr><td rowspan="1" colspan="1">iNOS</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">(0.00 &#x02013; 0.00)</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">(0.00 &#x02013; 0.00)</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">(0.00 &#x02013; 0.00)</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">(0.00 &#x02013; 0.00)</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><attrib>Source: Data generated by the author.</attrib><fn id="TFN7"><p>The values correspond to the following nomenclature: mean (&#x000b1; 95% CI).</p></fn><fn id="TFN8"><p>*Friedman test.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Report from the Wills Eye Hospital at Florida demonstrated prevalence of 62% of adenoviral conjunctivitis amongst all subjects presenting clinical diagnosis of infectious conjunctivitis<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B15" ref-type="bibr">15</xref></sup> . Viruses are associated with up to 80% of all prevalence of acute conjunctivitis<sup><xref rid="B16" ref-type="bibr">16</xref> - <xref rid="B20" ref-type="bibr">20</xref></sup> .</p><p>65 to 90% of cases of viral conjunctivitis are caused by adenoviruses, and it produces two common clinical symptoms related to viral conjunctivitis: pharyngoconjunctival fever (high fever, pharyngitis and bilateral conjunctivitis) and keratoconjunctivitis (lymphadenopathy). In another report from Southeastern Brazil, in Sao Paulo, the authors found a prevalence of 59.0% with acute conjunctivitis associated with adenovirus diagnosed by PCR<sup><xref rid="B21" ref-type="bibr">21</xref></sup> . In addition, in Northeastern Brazil, in Fortaleza, a study assessing 24 patients demonstrated that 12 (50%) tested positively for viral infection<sup><xref rid="B22" ref-type="bibr">22</xref></sup> .</p><p>This report did not show any significant differences between treatment with NSAID and steroids in signs of conjunctivitis. Keratoconjunctivitis is frequently associated with outbreaks, and is also commonly related to the adenovirus serotypes<sup><xref rid="B25" ref-type="bibr">25</xref> , <xref rid="B26" ref-type="bibr">26</xref></sup> .</p><p>The treatment of keratoconjunctivitis targets reduction in redness, itching, tearing, blurry vision, chemosis and eyelid oedema<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B26" ref-type="bibr">26</xref></sup> . To this end, there are a variety of topical preparations, each working on a different phase in the inflammatory process, in order to manage those signs<sup><xref rid="B28" ref-type="bibr">28</xref></sup> . The treatment of conjunctivitis includes steroids<sup><xref rid="B23" ref-type="bibr">23</xref></sup> and NSAID<sup><xref rid="B24" ref-type="bibr">24</xref></sup> . This report aimed to demonstrate that the use of anti-inflammatory NSAIDs or corticosteroid could improve the inflammatory status in eye mucosa during conjunctivitis. However, the study could not demonstrate a statistical difference between the treatments. Nevertheless, the report found a clinical trend in the third evaluation between the groups A compared to group B.</p><p>In another similar report evaluating sixty patients clinically diagnosed with a different kind of conjunctivitis [Seasonal Allergic Conjunctivitis (SAC)], the patients were treated with diclofenac (0.1%) and ketorolac (0.5%), and the authors demonstrated an improvement on the symptoms (e.g., burning/stinging, discharge / tearing, photophobia, foreign body sensation and swollen eye) in both treatments. In final analysis the therapeutic response did show an improvement on incomes in group treated with ketorolac (0.5%)<sup><xref rid="B28" ref-type="bibr">28</xref></sup> . On the other hand, in a study from Recife, Brazil, the authors, evaluating fifty patients with symptoms of acute viral conjunctivitis, a group of twenty-four patients treated with ketorolac (0.45%) plus carboximetilcelulose and the other group with twenty-six patients received artificial tears, demonstrated no statistical difference between the two types of treatment<sup><xref rid="B29" ref-type="bibr">29</xref></sup> .</p><p>Nevertheless Swany <italic>et al</italic> .<sup><xref rid="B30" ref-type="bibr">30</xref></sup> , analyzing eight clinical studies with 712 patients involved with allergic conjunctivitis, demonstrated that use of NSAID produced significant relief of inflammatory conjunctival itching; however, for the other inflammatory signs (e.g. ocular burning/pain, eyelid swelling, photophobia and foreign sensation), the data were not significant, similar to the findings of this study.</p><p>Thus, based on this report there is limited evidence to support the use of topical NSAID in viral acute conjunctivitis. Further studies are needed to compare the efficacy of non-hormonal anti-inflammatory, hormonal (steroid) and non-use of anti-inflammatory in acute epidemic and endemic conjunctivitis, through dosage of inflammatory mediators, and clinical status using a higher number of patients.</p><p>In this report, no equivalent work was found, being considered the first research in this specific aim. Our observation suggests that in the current study, there was a clinical difference in the group treated with corticoid; however, it was not statistically significant.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>There was no statistical difference between the treatments tested, but in the clinical symptoms of the patients, we can report that there was a clinical trend of improvement for those who received corticosteroid.</p></sec></body><back><ack><title>Acknowledgement</title><p>To Dr. David Bollick (University of Virginia) for his English considerations. We appreciate the time spent reading and correcting our article.</p></ack><fn-group><fn fn-type="other" id="fn1"><label>1</label><p>Research performed at Hospital de Olhos Leiria de Andrade, Fortaleza-CE, Brazil.</p></fn></fn-group><fn-group><fn fn-type="supported-by"><p>Financial source: none</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>HE</given-names></name></person-group><article-title>Adenovirus advances: new diagnostic and therapeutic options</article-title><source>Curr Opin Ophthal</source><year>2011</year><volume>22</volume><issue>4</issue><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1097/ICU.0b013e3283477cb5</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>T</given-names></name><name><surname>Sloane</surname><given-names>PD</given-names></name></person-group><article-title>A comparison of eye problems in primary care and ophthalmology practices</article-title><source>Fam Med</source><year>1991</year><volume>23</volume><issue>7</issue><fpage>544</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">1936738</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udeh</surname><given-names>BL</given-names></name><name><surname>Schneider</surname><given-names>JE</given-names></name><name><surname>Ohsfeldt</surname><given-names>RL</given-names></name></person-group><article-title>Cost effectiveness of a point-of-care test for adenoviral conjunctivitis</article-title><source>Am J Med Sci</source><year>2008</year><volume>336</volume><issue>3</issue><fpage>254</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e3181637417</pub-id><pub-id pub-id-type="pmid">18794621</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>S</given-names></name><name><surname>Cabrera-Aguas</surname><given-names>M</given-names></name><name><surname>Khoo</surname><given-names>P</given-names></name></person-group><article-title>Common eye infections</article-title><source>Aust Prescr</source><year>2018</year><volume>41</volume><issue>3</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.18773/austprescr.2018.016</pub-id><pub-id pub-id-type="pmid">29922000</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f8;vding</surname><given-names>G</given-names></name></person-group><article-title>Acute bacterial conjunctivitis</article-title><source>Acta Ophthalmol</source><year>2008</year><volume>86</volume><issue>1</issue><fpage>5</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0420.2007.01006.x</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azari</surname><given-names>AA</given-names></name><name><surname>Barney</surname><given-names>NP</given-names></name></person-group><article-title>Conjunctivitis: a systematic review of diagnosis and treatment</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>16</issue><fpage>1721</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.280318</pub-id><pub-id pub-id-type="pmid">24150468</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname><given-names>JJ</given-names></name><name><surname>Morcillo-Laiz</surname><given-names>R</given-names></name><name><surname>Mu&#x000f1;oz-Negrete</surname><given-names>FJ</given-names></name></person-group><article-title>Adenoviral keratoconjunctivitis: an update</article-title><source>Arch Soc Esp Oftalmol (English Edition)</source><year>2013</year><volume>88</volume><issue>3</issue><fpage>108</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.oftale.2012.07.002</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azar</surname><given-names>MJ</given-names></name><name><surname>Dhaliwal</surname><given-names>DK</given-names></name><name><surname>Bower</surname><given-names>KS</given-names></name><name><surname>Kowalski</surname><given-names>RP</given-names></name><name><surname>Gordon</surname><given-names>YJ</given-names></name></person-group><article-title>Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis</article-title><source>Am J Ophthalmol</source><year>1996</year><volume>121</volume><issue>6</issue><fpage>711</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(14)70640-3</pub-id><pub-id pub-id-type="pmid">8644817</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Farrar</surname><given-names>JA</given-names></name><name><surname>Hurwitz</surname><given-names>E</given-names></name><name><surname>Hierholzer</surname><given-names>J</given-names></name><name><surname>Ford</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name></person-group><article-title>A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread</article-title><source>J Infect Dis</source><year>1989</year><volume>160</volume><issue>6</issue><fpage>938</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1093/infdis/160.6.938</pub-id><pub-id pub-id-type="pmid">2555421</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skevaki</surname><given-names>CL</given-names></name><name><surname>Galani</surname><given-names>IE</given-names></name><name><surname>Pararas</surname><given-names>MV</given-names></name><name><surname>Giannopoulou</surname><given-names>KP</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name></person-group><article-title>Treatment of viral conjunctivitis with antiviral drugs</article-title><source>Drugs</source><year>2011</year><volume>71</volume><issue>3</issue><fpage>331</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.2165/11585330-000000000-00000</pub-id><pub-id pub-id-type="pmid">21319870</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>M</given-names></name></person-group><article-title>Conjunctivitis: diagnosis and management</article-title><source>Community Eye Health</source><year>1999</year><volume>12</volume><issue>30</issue><fpage>19</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">17491982</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toker</surname><given-names>MI</given-names></name><name><surname>Erdem</surname><given-names>H</given-names></name><name><surname>Erdogan</surname><given-names>H</given-names></name><name><surname>Arici</surname><given-names>MK</given-names></name><name><surname>Topalkara</surname><given-names>A</given-names></name><name><surname>Arslan</surname><given-names>OS</given-names></name><name><surname>Pahsa</surname><given-names>A</given-names></name></person-group><article-title>The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><issue>5</issue><fpage>902</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2005.12.004</pub-id><pub-id pub-id-type="pmid">16527227</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiuey</surname><given-names>Y</given-names></name><name><surname>Ambati</surname><given-names>BK</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><collab>Viral Conjunctivitis Study Group</collab></person-group><article-title>A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><issue>8</issue><fpage>1512</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(00)00177-9</pub-id><pub-id pub-id-type="pmid">10919900</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambursky</surname><given-names>RP</given-names></name><name><surname>Fram</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name></person-group><article-title>The prevalence of adenoviral conjunctivitis at the Wills Eye Hospital Emergency Room</article-title><source>Optometry</source><year>2007</year><volume>78</volume><issue>5</issue><fpage>236</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.optm.2006.11.012</pub-id><pub-id pub-id-type="pmid">17478342</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambursky</surname><given-names>R</given-names></name><name><surname>Tauber</surname><given-names>S</given-names></name><name><surname>Schirra</surname><given-names>F</given-names></name><name><surname>Kozich</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>EJ</given-names></name></person-group><article-title>The RPS adeno detector for diagnosing adenoviral conjunctivitis</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><issue>10</issue><fpage>1758</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2006.06.029</pub-id><pub-id pub-id-type="pmid">17011956</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenson</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>R</given-names></name><name><surname>Fedukowicz</surname><given-names>H</given-names></name></person-group><article-title>Laboratory studies in acute conjunctivitis</article-title><source>Arc Ophthalmol</source><year>1982</year><volume>100</volume><issue>8</issue><fpage>1275</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1001/archopht.1982.01030040253009</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f6;nnerstam</surname><given-names>R</given-names></name><name><surname>Persson</surname><given-names>KE</given-names></name><name><surname>Hansson</surname><given-names>HO</given-names></name><name><surname>Renmarker</surname><given-names>K</given-names></name></person-group><article-title>Prevalence of chlamydial eye infection in patients attending an eye clinic, a VD clinic, and in healthy persons</article-title><source>Br J Ophthalmol</source><year>1985</year><volume>69</volume><issue>5</issue><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1136/bjo.69.5.385</pub-id><pub-id pub-id-type="pmid">3838901</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>SP</given-names></name><name><surname>Mallinson</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Clearkin</surname><given-names>LG</given-names></name></person-group><article-title>Adult follicular conjunctivitis and neonatal ophthalmia in a Liverpool eye hospital, 1980&#x02013;1984</article-title><source>Eye</source><year>1987</year><volume>1</volume><issue>4</issue><size units="pages">512</size><pub-id pub-id-type="doi">10.1038/eye.1987.77</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchio</surname><given-names>E</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name></person-group><article-title>Clinical and epidemiological features of acute follicular conjunctivitis with special reference to that caused by herpes simplex virus type 1</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><issue>9</issue><fpage>968</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1136/bjo.84.9.968</pub-id><pub-id pub-id-type="pmid">10966946</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodland</surname><given-names>RM</given-names></name><name><surname>Darougar</surname><given-names>S</given-names></name><name><surname>Thaker</surname><given-names>U</given-names></name><name><surname>Cornell</surname><given-names>L</given-names></name><name><surname>Siddique</surname><given-names>M</given-names></name><name><surname>Wania</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name></person-group><article-title>Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan</article-title><source>Trans R Soc Trop Med Hyg</source><year>1992</year><volume>86</volume><issue>3</issue><fpage>317</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(92)90328-A</pub-id><pub-id pub-id-type="pmid">1412664</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>RD</given-names></name><name><surname>Lira</surname><given-names>RP</given-names></name><name><surname>Arieta</surname><given-names>CE</given-names></name><name><surname>Castro</surname><given-names>RS</given-names></name><name><surname>Bonon</surname><given-names>SH</given-names></name></person-group><article-title>The prevalence of adenoviral conjunctivitis at the Clinical Hospital of the State University of Campinas, Brazil</article-title><source>Clinics</source><year>2015</year><volume>70</volume><issue>11</issue><fpage>748</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.6061/clinics/2015(11)06</pub-id><pub-id pub-id-type="pmid">26602522</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname><given-names>FE</given-names></name><name><surname>Ribeiro</surname><given-names>DC</given-names></name><name><surname>Gurgel</surname><given-names>N</given-names></name><name><surname>da Silva Mendes</surname><given-names>AC</given-names></name><name><surname>Tavares</surname><given-names>FN</given-names></name><name><surname>Tim&#x000f3;teo</surname><given-names>CN</given-names></name><name><surname>da Silva</surname><given-names>EE</given-names></name></person-group><article-title>Acute hemorrhagic conjunctivitis outbreak in the city of Fortaleza, northeast Brazil</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><issue>9</issue><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1136/bjo.2006.098822</pub-id><pub-id pub-id-type="pmid">16809381</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>MR</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Bunce</surname><given-names>C</given-names></name><name><surname>Khawaja</surname><given-names>A</given-names></name><name><surname>Siriwardena</surname><given-names>D</given-names></name><name><surname>Larkin</surname><given-names>DF</given-names></name></person-group><article-title>A randomized placebo-controlled trial of topical steroid in presumed viral conjunctivitis</article-title><source>Br J Ophthalmol</source><year>2011</year><volume>95</volume><issue>9</issue><fpage>1299</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1136/bjo.2010.188623</pub-id><pub-id pub-id-type="pmid">21252084</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schechter</surname><given-names>BA</given-names></name></person-group><article-title>Ketorolac tromethamine 0.4% as a treatment for allergic conjunctivitis</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2008</year><volume>4</volume><issue>4</issue><fpage>507</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.4.507</pub-id><pub-id pub-id-type="pmid">18433352</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>XH</given-names></name><name><surname>Ishiko</surname><given-names>H</given-names></name><name><surname>Ha</surname><given-names>NT</given-names></name><name><surname>Ohguchi</surname><given-names>T</given-names></name><name><surname>Akanuma</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name></person-group><article-title>Molecular epidemiology of adenoviral conjunctivitis in Hanoi, Vietnam</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><issue>6</issue><fpage>1064</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2006.07.041</pub-id><pub-id pub-id-type="pmid">17157595</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>AL</given-names></name><name><surname>Chodosh</surname><given-names>J</given-names></name></person-group><article-title>Adenoviral keratoconjunctivitis in a tertiary care eye clinic</article-title><source>Cornea</source><year>2006</year><volume>25</volume><issue>2</issue><fpage>199</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1097/01.ico.0000170693.13326.fb</pub-id><pub-id pub-id-type="pmid">16371782</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenaerts</surname><given-names>L</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name><name><surname>Naesens</surname><given-names>L</given-names></name></person-group><article-title>Clinical features and treatment of adenovirus infections</article-title><source>Rev Med Virol</source><year>2008</year><volume>18</volume><issue>6</issue><fpage>357</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1002/rmv.589</pub-id><pub-id pub-id-type="pmid">18655013</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehar</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name></person-group><article-title>Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis</article-title><source>Int J Appl Basic Med Res</source><year>2012</year><volume>2</volume><issue>1</issue><size units="pages">25</size><pub-id pub-id-type="doi">10.4103/2229-516X.9679</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyra</surname><given-names>AF</given-names></name><name><surname>Bastos</surname><given-names>LC</given-names></name><name><surname>Lima</surname><given-names>RC</given-names></name><name><surname>Maranh&#x000e3;o</surname><given-names>LD</given-names></name><name><surname>Arantes</surname><given-names>TE</given-names></name></person-group><article-title>Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis</article-title><source>Arq Bras Oftamlmol</source><year>2014</year><volume>77</volume><issue>2</issue><fpage>99</fpage><lpage>102</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swamy</surname><given-names>BN</given-names></name><name><surname>Chilov</surname><given-names>M</given-names></name><name><surname>McClellan</surname><given-names>K</given-names></name><name><surname>Petsoglou</surname><given-names>C</given-names></name></person-group><article-title>Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data</article-title><source>Ophthalmic Epidemiol</source><year>2007</year><volume>14</volume><issue>5</issue><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1080/09286580701299411</pub-id><pub-id pub-id-type="pmid">17994441</pub-id></element-citation></ref></ref-list></back></article>